It was also proposed by the in vivo experiment that the siglec‐15 deficient mice was resistive to tumor growth by promoting the responses of T cells,82 and siglec‐15 is recommended to be a promising target for normalized cancer immunotherapy.83 programmed cell death ligand 1 (PD‐L1), a ligand for T‐cell inhibitory receptor PD‐1, was suggested to be an active agent in the immune suppression. The gene discussed is CD274; the disease is cancer.